2014
DOI: 10.1016/j.diabres.2014.08.012
|View full text |Cite
|
Sign up to set email alerts
|

LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: A retrospective analysis

Abstract: These results suggest the possibilities which LDL-apheresis is considered to contribute to survival extension and renal function maintenance of severe diabetic nephropathy patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
9
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 21 publications
1
9
0
Order By: Relevance
“…[1][2][3] On the contrary, it has been reported that the effectiveness of LDL-A is not significantly different between FSGS and non-FSGS 4 and that LDL-A effectively decreases proteinuria and podocyte excretion, 5 which affects survival extension and renal function in diabetic nephropathy patients. 6 The effectiveness of LDL-A lies in reducing serum low-density lipoprotein; LDL-A may also have various other benefits. [1][2][3][4][5][6] Muso et al proposed that LDL-A improves hypercoagulability and renal hemodynamics and that LDL-A contributes to the therapeutic effect of antiproteinuric drugs such as corticosteroids.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[1][2][3] On the contrary, it has been reported that the effectiveness of LDL-A is not significantly different between FSGS and non-FSGS 4 and that LDL-A effectively decreases proteinuria and podocyte excretion, 5 which affects survival extension and renal function in diabetic nephropathy patients. 6 The effectiveness of LDL-A lies in reducing serum low-density lipoprotein; LDL-A may also have various other benefits. [1][2][3][4][5][6] Muso et al proposed that LDL-A improves hypercoagulability and renal hemodynamics and that LDL-A contributes to the therapeutic effect of antiproteinuric drugs such as corticosteroids.…”
Section: Discussionmentioning
confidence: 99%
“…[1][2][3] Several studies have reported that LDL-A may be effective for non-FSGS or for diabetic nephropathy. [4][5][6] Minimal change disease (MCD) often causes NS not only in children but also in adults. [7][8][9] Renal insufficiency occurs in approximately 20-30% of patients with MCD.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Several reports have evaluated the efficacy of LDL-A for non-FSGS diseases, such as MCNS [ 12 ], membranous nephropathy [ 13 , 14 ], lupus nephritis [ 15 , 16 , 17 ], and diabetic nephropathy [ 18 , 19 , 20 , 21 ], but most are case reports/series with a limited number of subjects. Although the number of subjects with each disease apart from FSGS is small, we examined a total of 16 subjects with non-FSGS registered in the POLARIS cohort and found that LDL-A treatment reduced the UP level in those patients at a comparable rate to that in FSGS cases immediately after treatment [ 10 ].…”
Section: Discussionmentioning
confidence: 99%
“…The American Society for Apheresis has published a guideline document indicating that lipoprotein apheresis could be of use in focal segmental glomerulosclerosis, sudden sensorineural hearing loss, and phytanic acid storage disease . Lipoprotein apheresis has also shown promising results in treatment of nephropathy in diabetes mellitus and nephrotic syndrome of various etiologies . It has been suggested that lipoprotein apheresis can reduce the risk of in‐stent coronary restenosis in the early postimplantation period, and also have favorable effects in patients with critical limb ischemia due to below‐knee arterial lesions .…”
Section: Introductionmentioning
confidence: 99%